A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics

PHASE1UnknownINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 29, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2023

Conditions
Rhizomelic Chondrodysplasia Punctata
Interventions
DRUG

PPI-1011

PPI-1011 is a liquid oil with light yellow to amber color, clear to slightly opalescent and flows readily at room temperature. It is insoluble in water and miscible with dichloromethane and liquid coconut oil. It is a synthetic glycerolipid derivative, comprised of an assembly of naturally-occurring products including glycerol backbone, an ether-linked hexadecyl group at sn1 position, an all-cis-4, 7, 10, 13, 16, 19-docosahexaenoyl group at sn2 position, and a lipoyl group at sn3 position. It was designed as a plasmalogen precursor and is similar in structure to naturally occurring alkyl-diacyl lipids with the primary difference being the presence of a lipoic acid moiety at the sn3 position. PPI-1011 is formulated in liquid coconut oil containing 0.1% 1-thioglycerol as an antioxidant.

DRUG

Placebo

Placebo

Trial Locations (1)

M9L 3A2

RECRUITING

Biopharma Services Inc., Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioPharma Services Inc.

INDUSTRY

lead

MED-LIFE DISCOVERIES LP

INDUSTRY